La matinée du lundi 25 novembre était sous le signe du CES Las Vegas 2025 avec l’organisation d’une conférence de presse, la dernière réunion de préparation et la rencontre de la délégation 2025 à l’Hôtel de Région de Lyon, organisé par la Région Auvergne-Rhône-Alpes et Minalogic.
NETRI, an industrial start-up based in Lyon (France), has been awarded the highly coveted Innovation Award from CES Las Vegas for its pioneering platform, NeuroFluidics™ Care. This platform is transforming biochemical safety assessments, enabling early toxicity analysis of compounds used by the food industry with unprecedented precision and accessibility.
We’re excited and proud to launch our new quarterly newsletter!
To make sure you receive it, please sign up.
The FDA’s Center for Drug Evaluation and Research (CDER) has accepted the first letter of intent (LOI) into its ISTAND Pilot Program for organs-on-chip technology. This LOI is for a human Liver-Chip used to assess the risk of DILI in adults to create relevant data for a drug’s investigational new drug (IND) submission. This LOI acceptance marks a major step forward for CIVM in general.
NETRI, une start-up industrielle qui développe des organes sur puce pour les industries de la santé, annonce aujourd’hui la formation de son Conseil Scientifique (SAB) et la nomination inaugurale du Dr Myriam Guiral et du Dr Nicolas Aznar. Les membres du SAB fourniront à NETRI des informations et des conseils sur l’orientation scientifique. Aujourd’hui, le SAB de NETRI se réunit pour la première fois avec les équipes NETRI afin de partager leur vision unique de l’état de l’art et des marchés en l’oncologie et culture en 3D (organoïdes).
NETRI, an industrial start-up that develops organs-on-chip for health industries, today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointment of Dr. Myriam Guiral and Dr. Nicolas Aznar. The SAB members will provide insight and guidance to NETRI on the scientific orientation. Today, NETRI’s SAB is meeting for the first time with NETRI teams to benefit from their unique insight in Oncology and Organoids state of the art and markets.
ORGANS-ON-CHIP KITS
Quickly and easily adopt organs-on-chip
into users’ research
